Hurricane Gustav poses first real test for Rx Response
This article was originally published in Scrip
Hurricane Gustav's landfall on the US Gulf Coast on September 1st marked the first time the pharmaceutical industry's new Rx Response co-ordination programme was activated, but so far drug and biological manufacturers have not been asked to send emergency medicines to the affected region.
You may also be interested in...
With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.
La Jolla’s formulation appears blocked by Amivas’ seven-year orphan exclusivity, and the company also will miss out on chance for a tropical disease priority review voucher; Amivas worked with the US Army to bring the severe malaria treatment through final stages of development and regulatory review.
Amivas requested a US tropical disease PRV for intravenous artesunate but FDA has not yet made a decision on eligibility; approval appears to block La Jolla’s competing product, currently under review, for seven years.